BioWorld

March 22, 2005

Onyx, Bayer Plan To File NDA For Sorafenib On Interim Data

Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. plan to file for FDA approval of BAY 43-9006, which has been renamed sorafenib, based on interim Phase IIII data from a study in advanced kidney cancer patients. (BioWorld Today) Read More

Sequoia Raises $22M To Fund Programs In Viral Infections

Avastin Competitor Misses Endpoint; Genentech Jumps

Biolex Signs Up Centocor In Wide-Ranging Protein Deal

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Medical illustration showing layers of a blood vessel

Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

BioWorld Science

More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...

Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

BioWorld Science

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...